Type 8 isoquinoliniumzwitterions were synthesised by the reaction of type 1 diketones or type 2 pyrylium salts with different 5-amino-3-Q-1H-1,2,4-triazoles. Spectroscopic and X-ray diffraction evidence was given for the zwitterion structure of the products obtained. The position of the negative charge on the 1,2,4-tiazolium ring was proved by comparison of the cmr and uv spectra of the products
This invention relates to novel triazolopyrimidine derivatives of formulae (Ia) and (Ib), ##STR1## wherein Q represents hydrogen, a heterocyclic group optionally substituted by a C.sub.1-4 alkyl group and containing one or more oxygen and/or nitrogen atoms or a group of formula --SR.sup.1 wherein R.sup.1 is alkyl or aralkyl, or a group of formula --NR.sup.2 R.sup.3 wherein R.sup.2 and R.sup.3 are independently hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl or a heterocyclic group, m and n are independently 0, 1, 2, 3 or 4, with the provision that if m stands for 0, then n is different from 0, and if both n and m are 1 or m stands for 0 and n is 2, the Q is different from methylthio or morpholino group, their mixtures or pharmaceutically acceptable salts. Furthermore, the invention relates to a process for preparing these compounds. The compounds of formulae (Ia) and (Ib) are able to inhibit the ptosis caused by tetrabenazine and they have analgetic activity.
Biguanide compositions and methods of treating metabolic disorders
申请人:Elcelyx Therapeutics, Inc.
公开号:US10028923B2
公开(公告)日:2018-07-24
Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.